Drug intelligence / Profile preview

BMS-986488 + adagrasib

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-986488 + adagrasib is an investigational combination therapy comprising BMS-986488, a novel agent under development by Bristol Myers Squibb, and adagrasib, a small molecule inhibitor of KRAS G12C. This combination is currently being studied for safety, tolerability, and anti-cancer activity in patients with advanced malignant solid tumors, notably those harboring the KRAS G12C mutation, including non-small cell lung cancer (NSCLC) and colorectal cancer. The mechanism of BMS-986488 has not been publicly disclosed, while adagrasib is known to function as a covalent inhibitor of KRAS G12C mutant protein[1][3][5][7].

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on BMS-986488 + adagrasib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986488 + adagrasib.

Explore the full profile